A PYMNTS Company

UK: Glaxo fined $54.3 million in ‘pay-for-delay’ antitrust probe

By  |  February 14, 2016

GlaxoSmithKline was fined 37.6 million pounds by the United Kingdom’s antitrust watchdog over pay-for-delay deals that held back sales of cheaper, generic versions of its anti-depressant Seroxat.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The London-based drugmaker colluded with other companies from 2001 to 2004 by agreeing to make payments “and other value transfers totaling over 50 million pounds to suppliers of generic versions of paroxetine,” the Competition and Markets Authority said in a statement Friday.

    “These ‘pay-for-delay’ agreements deferred the competition that the threat of independent generic entry could offer, and potentially deprived the National Health Service of the significant price falls that generally result from generic competition,” the CMA said. “In this case, when independent generic entry eventually took place at the end of 2003, average paroxetine prices dropped by over 70 percent in two years.”

    Antitrust regulators on both sides of the Atlantic for years have focused on how settlements between companies that make branded medicines and generics producers might harm consumers.

    Full content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.